1. Introduction {#sec1}
===============

Autologous cell-based products used to treat patients as a part of regenerative medicine or cell therapy are produced by one of two groups in Japan, based on new laws that came into effect in 2014 [@bib1], [@bib2]. One of these groups, which markets authorized products, has been certified for safety and efficacy by a licensed company, according to the Pharmaceutical Affairs Act [@bib3]. In general, a product destined for patients that have received regulatory approval are manufactured in the only factory that is certified as having Good Manufacturing Practice for the cell-based product (GCTP; Good Gene, Cellular, and Tissue-based Products Manufacturing Practice). When a product is prepared in the factory, the raw material, which is collected from a patient, is shipped from a medical institution that may be located anywhere throughout the country. On the other, cell-based products can be prepared for use in medical professionals\' practices and clinical studies, as outlined in the Act on the Safety of Regenerative Medicine (RM Safety Act), and these uses come under the jurisdiction of the Medical Practitioners' Act and the Medical Care Act. According to the RM Safety Act, medical professionals need to be responsible for the safety of the treatment containing the cell-based product, so the product does not receive regulatory approval at the company level. Instead, each treatment is planned and performed by a specific medical institution, and the location at which the raw materials are collected and transplanted is determined by the medical institution. The cell-based products are prepared at the medical institution or by a licensed manufacturing company. Licensed manufacturing companies are inspected by the Pharmaceuticals Medical Devices Agency (PMDA) to check that they adhere to the relevant requirements.

When an autologous cell-based product is prepared as an authorized product, the quality has to be uniform, and variations in manufacturing need to be fine-tuned for each product [@bib4]. The quality of these raw materials is variable and depends on individual patient differences, while additional variation can occur because of transportation from the location where the raw materials were collected. At present, relatively few products manufactured in this way have received regulatory approval. Therefore, sharing knowledge based on the manufacturing of autologous cell-based products for clinical treatment under the RM Safety Act in Japan is invaluable for quality management.

Several medical institutions in different locations can request a similar, not authorized, cell-based product, which have a single manufacturing method, from a licensed manufacturing company under the RM Safety Act. Each of them is considered to be unique in each according to the regulation, but we think that useful manufacturing information can be obtained by performing a combined quantitative analysis of these individual cases. In this study, variations in manufacturing reproducibility depending on transit time were investigated in a cell-based product manufactured using a single method, based on raw materials containing individual differences that were collected by two medical institutions located in different areas.

2. Methods {#sec2}
==========

2.1. Expansion of activated natural killer (NK) cells {#sec2.1}
-----------------------------------------------------

All of the manufacturing was carried out at the cell processing facility (CPF) of the Biotherapy Institute of Japan (BIJ) in Tokyo, Japan [@bib5]. Activated NK cells were expanded using an expansion kit (BINKIT®, BIJ, Japan), as described below [@bib6], [@bib7]. The quality tests used to identify NK cells via surface markers and the safety test used to check for microbial contamination are not described here. Blood mononuclear cells were isolated from 50 mL of peripheral blood by density gradient centrifugation using Ficoll--Paque (GE Healthcare, Sweden). For the initial activation, the isolated peripheral blood mononuclear cells (PBMCs) were cultured in BINKIT® initial medium plus 5% heat-inactivated autologous plasma in a BINKIT® initial cocktail in a BINKIT® culture flask. After 3 days of cultivation, the cells were transferred to a culture flask containing BINKIT® subculture medium. Fresh culture medium was added to the flask every 2 or 3 days. Around day 9 (intermediate day), the cells were counted and transferred to a culture bag (NIPRO, Japan) for logarithmic growth. The cells were grown in an incubator (Astec, Japan) at 37 °C in a humidified 5% CO~2~ atmosphere. The cells were cultured for approximately 3 weeks, after which a quality check was performed to confirm that more than 1 × 10^9^ cells were obtained; the exact number of cells differed based on inter-patient variability. The cells were then transferred to an infusion bag (Terumo, Japan) filled with Ringer\'s solution (Otsuka Pharmaceutical, Japan) and shipped to the medical institution.

2.2. NK cell manufacturing for clinical use at clinic A {#sec2.2}
-------------------------------------------------------

Clinic A is located in Tokyo, Japan. Peripheral blood collected from patients at this clinic was transported to BIJ at room temperature, and PBMCs isolation began the same day. The standard culture period for PBMCs was 21 days, but in some cases this varied depending on the diagnosis made by the doctor. After the prescribed culture period was complete and the quality check was performed according to the doctor\'s instructions, the cells were shipped back to the clinic under refrigerated conditions.

2.3. NK cell manufacturing for clinical use at clinic B {#sec2.3}
-------------------------------------------------------

Clinic B is located in Fukushima, Japan. Peripheral blood collected from patients at this clinic was shipped overnight to BIJ at room temperature, and PBMCs isolation began the next day (around 24 hours after the blood was collected). The standard culture period for the PBMCs was 19 days, but in some cases this varied depending on the diagnosis made by the doctor. After the prescribed culture period was complete and the quality check was performed according to the doctor\'s instructions, the cells were shipped back to the clinic under refrigerated conditions.

2.4. Selection criteria for selecting the manufacturing case {#sec2.4}
------------------------------------------------------------

For the purpose of this study, the above NK cell manufacturing was chosen as a representative cell-based product manufacturing process. The donors were cancer patients, and none of the donors had a history of anticancer drug treatment or radiation therapy. For several of the donors, more than one sample was submitted for manufacturing.

2.5. Calculation of apparent specific growth rate, *μ*^app^ {#sec2.5}
-----------------------------------------------------------

In general, the specific growth rate is equivalent to the growth rate of cultured cells in the exponential growth phase. However, the cells grown for this study did not be counted during the exponential growth phase. Instead, the *μ*^app^ was calculated based on the cell growth rate during the early or late phases, using the following equation [(1)](#fd1){ref-type="disp-formula"}.$$\mu^{app} = \frac{\ln N_{2} - \ln N_{1}}{t_{2} - t_{1}}$$where *N*~1~ and *N*~2~ are the total number of living cells on the first cell counting day (*t*~1~) and the second cell counting day (*t*~2~) of culture, respectively. The cell counting quality checks were performed three times during the culture period (that is, first day, last day, and their intermediate day).

3. Results {#sec3}
==========

3.1. Cell manufacturing at a cell processing facility {#sec3.1}
-----------------------------------------------------

Activated immune cells containing mainly natural killer cells for clinical use were ordered by two clinics based in two different locations and manufactured in the same cell processing facility (CPF). In total, 456 batches of cells (from 151 patients) were processed in the CPF using the same production method over a period of four years from April 2013 to March 2017 ([Table 1](#tbl1){ref-type="table"}). Clinic A, which is located 4 km from the CPF, sent 164 samples, and clinic B, which is 203 km from the CPF, sent 292 samples. Cell product manufacturing from the raw material (peripheral blood) began the day the blood was collected in the case of clinic A, and approximately 24 hours after collection in the case of clinic B. The cell counts of the collected and expanded peripheral blood mononuclear cells (PBMCs) are shown in [Fig. 1](#fig1){ref-type="fig"}. All of the donors were cancer patients with no history of anticancer drug or radiation treatment. The average cell number, culture period and apparent specific growth rate (*μ*^app^) are shown in [Table 2](#tbl2){ref-type="table"}. The mean culture period was 21 days for clinic A, but 19 days for clinic B. Seven samples from clinic A (4.3%) and 33 samples from clinic B (11.3%) generated final products with less than the expected cell number (1 × 10^9^). Thus, the average number of cells in the final products manufactured for clinic A was higher than that in the products manufactured for clinic B. However, the average *μ*^app^ values during the whole culture period were 0.22 and 0.24 for clinic A and clinic B, respectively, indicating that the growth rate was slower in the cells from clinic A. The F-test value for equality of variances between clinic A and B was 1.5, indicating that was not equally distributed (\>*F*~0.05~).Table 1Number of samples and culture period duration for NK cell manufacturing in a CPF.Table 1Culture duration (day)18192021222324TotalSample from clinic A591096211211164Sample from clinic B18242311000292Fig. 1Total number of PBMCs throughout the manufacturing process. (A) Primary PBMCs collected from patients at clinic A. (B) Primary PBMCs collected from patients at clinic B. (C) PBMCs in final products manufactured from samples from clinic A. (D) PBMCs in final products manufactured from samples from clinic B.Fig. 1Table 2NK cell production manufacturing performance.Table 2Average total cell numberAverage culture period (day)Average *μ*^app^ (day^−1^)SD (day^−1^)F-testPrimary PBMCsFinal productSample from clinic A3.3 × 10^7^3.9 × 10^9^21.20.220.0301.5 (\>*F*~0.05~)Sample from clinic B3.1 × 10^7^3.1 × 10^9^19.10.240.036

3.2. Variation in *μ*^app^ in the early and late phases of cell growth {#sec3.2}
----------------------------------------------------------------------

The culturing period was divided into an early phase and a late phase, separated by transfer of the cells to a bag culturing system. The early phase lasted an average of 9 days, at which point the cell growth became stable. The *μ*^app^ values during the early and late phases (*μ*^E^ and *μ*^L^, respectively) are plotted in [Fig. 2](#fig2){ref-type="fig"}, and the incidence rate is summarized in [Fig. 3](#fig3){ref-type="fig"}. Two samples from clinic A (1.2%) and ten samples from clinic B (3.4%) were excluded, as their *μ*^E^ values were \<0. Even though the *μ*^E^ was less than 0 for these samples, their overall growth rates were near the average. Additionally, the final cell counts for over half of these samples (1 of 2 and 6 of 10 cases) reached the expected cell number. The results are summarized in [Table 3](#tbl3){ref-type="table"}. In the case of clinic A, the average *μ*^E^ was 0.17 with a standard deviation (SD) of 0.062, and the average *μ*^L^ was 0.27 with a SD was 0.053. In the case of clinic B, the average *μ*^E^ was 0.17 with a SD of 0.069, and the average *μ*^L^ was 0.31 with a SD of 0.053. The F-test value for equality of variances between clinic A and B was 1.3 for *μ*^E^ and 1.0 for *μ*^L^, indicating that each result was equally distributed (\<*F*~0.05~).Fig. 2Apparent specific growth rate (*μ*^app^). (A) The *μ*^app^ values of cells in the early phase (*μ*^E^), which lasted from cell isolation to the start of bag culturing, for samples from clinic A. (B) The *μ*^E^ values of samples from clinic B. (C) The *μ*^app^ values of cells in the late phase (*μ*^L^), which lasted from the start of bag culturing to the end of the culture period, for samples from clinic A. (D) The *μ*^L^ values for samples from clinic B.Fig. 2Fig. 3Incidence rate of the apparent specific growth rate (*μ*^app^). (A) The early phase (from cell isolation to starting the bag culture) for samples from clinic A. (B) The early phase for samples from clinic B. (C) The late phase (from starting the bag culture to the end of the culture period) for samples from clinic A. (D) The late phase for samples from clinic B.Fig. 3Table 3Summary of apparent specific growth rates (*μ*^app^) during NK cell manufacturing.Table 3Number of cases*μ*^app^ in the early phase (*μ*^E^)*μ*^app^ in the late phase (*μ*^L^)Deviation by *μ*^E^\<0Average (day^−1^)SD (day^−1)^F-testDeviation by *μ*^L^\<0Average (day^−1^)SD (day^−1^)F-testSample from clinic A16420.170.0621.3 (\<*F*~0.05~)00.270.0531.0 (\<*F*~0.05~)Sample from clinic B292100.170.06900.310.053

4. Discussion {#sec4}
=============

Under the Japanese Act on the Safety of Regenerative Medicine, medical institutions can request manufacturing of a cell-based product (non authorized preparation) using a single manufacturing method from a licensed manufacturing company. However, the detailed manufacturing conditions can vary depending on the clinic\'s location or the patient\'s individual treatment plan. Therefore, reproducibility verification is a very important part of the manufacturing process design and quality control for autologous cell-based products in the treatment plan. In this study, we used the apparent specific growth rate (*μ*^app^) as a performance index to quantitatively assess cell quality. This index can be calculated based on conventional cell counting methods, and as such can be applied universally across different cell types and processes [@bib8], [@bib9].

This study was tried to compare the influence due to the difference of manufacturing conditions for products in two clinics, whereas had been confirmed preliminary not to have sufficient differences statistically in the both of final products. Furthermore, there were two main differences between clinic A and clinic B in terms of the manufacturing process: one was the shipping procedure of raw materials and the other was the culture period. Thus, it was difficult to evaluate the difference in manufacturing efficiency between the clinics, as indicated by the *μ*^app^ values for total manufacturing period shown in [Table 2](#tbl2){ref-type="table"}. The influence of shipping conditions on cell growth should be clearly detectable in the early phase of growth, since differences in the proliferative potential of primary cells based on damage to individual cells is evident at the beginning of the culturing period [@bib10]. Therefore, for the purposes of this study, the manufacturing culture period was divided into two phases, before and after the 9th day, based on the quality check point for starting the bag culture process. The reasoning behind this decision is that the inherent specific growth rate of the collected cells becomes stable and cell-specific after day 9, whereas any cell damage that occurred during transport or storage may have a strong impact on the growth rate of the primary culture. As shown in [Fig. 2](#fig2){ref-type="fig"}, these growth rate distribution pattern was similar for the samples from both clinics in the early and late phases, although more samples from clinic B exhibited negative growth rates (*μ*^E^ \< 0) than those from clinic A in the early phase. It was supposed that the negative growth rates were occurred due to less proliferating living cells in the starting materials by unexpected factors on the collected blood. These samples were excluded from the summary shown in [Fig. 3](#fig3){ref-type="fig"} because as such did not exhibit an adequate *μ*^app^ value. Olson *et* *al.* reported that shipping cells at room temperature results in better viability, cell yield, and function, so we primarily focused on the impact of transit time in this study [@bib11]. While more than one cell product was manufactured from samples from several of the donors, differences between products generated from a single donor are not discussed here, as the sample size was small and variations with health problem could have occurred depending on the collection day.

Although the *μ*^E^ values were calculated to estimate the decay of raw materials by transit conditions, the average *μ*^E^ values for clinic A and clinic B were similar and significant difference was not obtained statistically. Then, amid these matters, it was supposed that there was a slight difference of the SDs between the clinics ([Table 3](#tbl3){ref-type="table"}). The SD should indicate individual differences and the influence of transit time. The SD for clinic B was higher than that for clinic A, despite the fact that a similar number of samples was collected from patients at both clinics. The proliferative potential of the primary cells from clinic B may have been more influenced by shipping than those from clinic A because of the overnight shipping. The states of influenced cells must exist between the state of viable and dead cells, and therefore, cell populations can be classified into four categories ([Fig. 4](#fig4){ref-type="fig"}), where injured or apoptotic cells would not proliferate at the beginning of the culturing period. These primary cells may have temporarily or permanently stopped the proliferating, as indicated by the higher rate of non-growing cell samples (*μ*^E^ \< 0) from clinic B compared with clinic A. The elevated SD for samples from clinic B may still be within the tolerance range for the process, because even though the *μ*^E^ values decreased, cell growth continued. A study by Posevitz-Fejfár *et* *al.* concluded that overnight shipping of blood samples does not alter the yield and viability of PBMCs isolated from the samples, so these shipment conditions could be suitable for manufacturing expanded PBMCs [@bib12]. However, if the transit time is longer than one day, the condition of cells might begin to deteriorate, making this an inappropriate shipping method for the manufacturing process explored here.Fig. 4Time-dependent cell decay model for transporting peripheral blood samples.Fig. 4

The average *μ*^L^ values were different between the samples from clinic A and clinic B, but they were equally distributed and the SDs were very similar for both clinics ([Table 3](#tbl3){ref-type="table"}). The *μ*^L^ values had a relatively standard normal distribution ([Fig. 3](#fig3){ref-type="fig"}). Since the *μ*^L^ value reflects the quality of the raw material, we predicted that the SDs for the two clinics would be similar and that the distribution of the *μ*^L^ values would be similar to that of the differences between individual donors. While the standard deviation reflects processing errors, the effect is expected to be relatively small because this culture method does not include any enzymatic passage treatments. The difference in the average *μ*^L^ values may be due to the standard culture period used for the samples from each clinic. The standard culture period was 21 days for samples from clinic A, whereas it was 19 days for samples from clinic B ([Table 1](#tbl1){ref-type="table"}). In autologous human cell culture, the growth rate often decreases after a certain period of time [@bib13]. Furthermore, the growth rate can decrease as cell density in the culture bag increases toward the end of the production process [@bib14]. Therefore, when *μ*^L^ values were classified according to the culture period, the results were obtained as shown in [Table 4](#tbl4){ref-type="table"}. And then we concluded that the difference in culturing time accounted for the shift in the average *μ*^L^ value. The total number of cells in the final product depends on the culture period, so the average total cell number from samples from clinic A was larger than that of samples from clinic B ([Table 2](#tbl2){ref-type="table"}).Table 4Summary of apparent specific growth rates in the late phase (*μ*^L^) for each culture period.Table 4Culture duration (day)18192021222324Average *μ*^L^ (day^−1^)0.330.310.310.270.240.240.25Number of samples232514197211211

5. Conclusions {#sec5}
==============

The results from this study suggest that variations in the proliferative potential of autologous mononuclear cells cultured in the same way are due to individual donor differences, and that the reproducibility of this manufacturing method is relatively high. Transit time had a small effect on the proliferative potential of mononuclear cells expanded from peripheral blood samples, and this effect was supposed to be most evident in the early phase of cell growth. While overnight shipping resulted in an increased rate of damaged samples, this effect was relatively small and most of the samples tested still exhibited reasonable growth rates. This shows that a transit time of 1 day at room temperature is acceptable for transporting peripheral blood a raw material in this manufacturing process.
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